Xencor Inc
XNCR
查看详细走势图
15.450USD
-0.020-0.13%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.10B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.13%
5天
-2.22%
1月
-7.71%
6月
+86.82%
今年开始到现在
-32.77%
1年
-36.39%
查看详细走势图
TradingKey Xencor Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Xencor Inc当前公司基本面数据相对稳定，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名52/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价28.00。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Xencor Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
14
位分析师
买入
评级
28.000
目标均价
+58.37%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Xencor Inc亮点
亮点风险
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
利润高增长
公司净利润处于行业前列，最新年度总收入110.49M美元
估值合理
公司最新PE估值-8.96，处于3年历史合理位
机构减仓
最新机构持股80.43M股，环比减少6.98%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值192.79K
Xencor Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Xencor Inc简介
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
公司代码XNCR
公司Xencor Inc
CEODahiyat (Bassil I)
网址https://xencor.com/
常见问题
Xencor Inc(XNCR)的当前股价是多少？
Xencor Inc(XNCR)的当前股价是 15.450。
Xencor Inc的股票代码是什么？
Xencor Inc的股票代码是XNCR。
Xencor Inc股票的52周最高点是多少？
Xencor Inc股票的52周最高点是24.940。
Xencor Inc股票的52周最低点是多少？
Xencor Inc股票的52周最低点是6.920。
Xencor Inc的市值是多少？
Xencor Inc的市值是1.10B。
Xencor Inc的净利润是多少？
Xencor Inc的净利润为-232.62M。
现在Xencor Inc(XNCR)的股票是买入、持有还是卖出？
根据分析师评级，Xencor Inc(XNCR)的总体评级为买入，目标价格为28.000。
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是多少
Xencor Inc(XNCR)股票的每股收益（EPS TTM）是-1.725。
相关品种
